At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Sirolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sirolimus Versus AntiVEGF for Wet AMD
In Brief
A Phase 2 clinical trial evaluating Sirolimus and Standard of Care intravitreal injections of anti-VEGF for Age-Related Macular Degeneration. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartApr 2015
Primary CompletionJan 2017
TodayJul 2026
First PostedFeb 6, 2015
Enrollment StartApr 1, 2015
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.4 years ago
Interventions
Sirolimusdrug
intravitreal injection
Standard of Care intravitreal injections of anti-VEGFdrug
intravitreal injections of anti-VEGF